Vraniak's career spans more than 20 years of financial and commercial experience in the life sciences industry.
Before joining Inversago, Vraniak served as chief financial officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on NASDAQ in February 2021, and successfully raised follow-on capital later that same year.
Prior to that, Vraniak served as the chief financial officer of electroCore, Inc. and was a key member of the management team that led the company through a successful IPO on NASDAQ in June 2018.
Additionally, Vraniak served as an executive in various innovative healthcare and technology companies including GE Capital, where he served as executive vice president.
Vraniak received an Electronic Engineering Technology degree and a Managerial MBA in Finance from the Rutgers University Center for Management Development.
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists.
Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy, Non-Alcoholic Steatohepatitis, complications from obesity, Hypertriglyceridemia, Type 1 Diabetes and Prader-Willi Syndrome, as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes